Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

计划入组 22 人 · 首次发布于 2017 年 1 月 11 日

Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort

计划入组 80 人 · 首次发布于 2024 年 2 月 13 日

[68 Ga]-DOTANOC PET/CT in GEP-NETs

计划入组 18 人 · 首次发布于 2015 年 11 月 18 日

Lutetium Lu 177 dotatate(Lutathera)

C₆₅H₈₇LuN₁₄O₁₉S₂

Lanreotide(Somatuline)

C₅₄H₆₉N₁₁O₁₀S₂ · Rx

NEST-3

Neos Therapeutics, LP

United States

Neos Therapeutics, Inc.

United States

Ness, Gregory M DDS

United States

NETTER-2 Trial: 177Lu-Dotatate Shows Promise but Raises Questions in High-Grade NETs

Sanofi, RadioMedix, and Orano Med Partner to Develop Radioligand Therapy for Rare Cancers

Lutetium-177 Dotatate Shows Promise in Neuroendocrine Tumors, Combination Strategies Explored